PTGFR prostaglandin F receptor
ENSG00000122420 · protein coding · Open Targets profile
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost. {ECO:0000250, ECO:0000269|PubMed:18587449}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 0.5734000205993652 (upper bound 0.8829299807548523). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 86 registry trials, updated in the last three years, of the most advanced drugs against PTGFR (dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, AL-12182), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Kerry StephensGlaukos Corporation · 3 of 3 trials Phase 2+
- Paul YooSpyGlass Pharma · 2 of 2 trials Phase 2+
- Tiffany E AngeloStony Brook University Hospital Department of Anesthesiology · 2 of 2 trials Phase 2+
- Anya LoncaricBausch & Lomb Incorporated · 1 of 1 trials Phase 2+
- Arthur J SitMayo Clinic · 1 of 1 trials Phase 2+
- Barbara M WirostkoQlaris Bio, Inc. · 1 of 1 trials Phase 2+
- Betsy Hughes-FormellaDermaliq Therapeutics, Inc. · 1 of 1 trials Phase 2+
- Carl B CamrasUNMC Department of Ophthalmology · 1 of 1 trials Phase 2+
- Carolina GracitelliFederal University of São Paulo · 1 of 1 trials Phase 2+
- Chris HafnerSpyGlass Pharma, Inc. · 1 of 1 trials Phase 2+
- David WirtaEye Research Foundation, Inc. · 1 of 1 trials Phase 2+
- Dilru AmarasekeraWills Eye Hospital Glaucoma Research · 1 of 1 trials Phase 2+
- Huaixing SunEye & ENT Hospital of Fudan University · 1 of 1 trials Phase 2+
- Jean-Sebastien GarrigueSanten SAS · 1 of 1 trials Phase 2+
- Josip PavanUniversity Hospital Dubrava · 1 of 1 trials Phase 2+
Registry trials of dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, AL-12182 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 72 of 80 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 6 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
42 trials of drugs against PTGFR were stopped early; 6 give no reason
Terminated, withdrawn and suspended interventional trials of dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, AL-12182, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 42.
- terminated · 2026-05-07 · Laboratorios Sophia S.A de C.V. · Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost“For interests of sponsor.”
- terminated · 2026-01-26 · Baylor Research Institute · matched by the registry's drug synonyms“Difficulty in acquiring patients in a reasonable amount of time.”
- terminated · 2025-10-15 · Massachusetts Eye and Ear Infirmary · Latanoprost eluting contact lens, Topical Latanoprost“Low recruitment”
- terminated · 2025-08-26 · University of Miami · Latanoprost, Bimatoprost, Travoprost“No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.”
- terminated · 2025-01-29 · Sight Sciences, Inc. · Latanoprost plus adjunctive glaucoma medication“Business decision by the Sponsor”
- terminated · 2024-08-23 · CT Glaucoma Associates · matched by the registry's drug synonyms“The 95% confidence interval for non-inferiority was met before planned enrollment was reached.”
- withdrawn · 2024-08-21 · Nova Scotia Health Authority · matched by the registry's drug synonyms“Did not submit to the REB”
- terminated · 2024-07-05 · Laboratorios Sophia S.A de C.V. · matched by the registry's drug synonyms“expiration time limit of recruitment”
- suspended · 2024-05-10 · JeniVision, Inc. · Latanoprost 0.005% Ophthalmic Solution“Awaiting transition to Part 2”
- withdrawn · 2024-03-04 · Bausch & Lomb Incorporated · Latanoprostene Bunod“It never started”
- terminated · 2023-12-21 · University of Nebraska · Latanoprost“Study stopped and data not analyzed”
- terminated · 2023-12-05 · Alcon Research · Travoprost 0.004% + Brinzolamide 1.0%, Travoprost 0.004% + Tears Natural“difficulty of enrolling patients”
- withdrawn · 2021-11-19 · Sun Pharmaceutical Industries Limited · matched by the registry's drug synonyms“[Sponsors decision]”
- withdrawn · 2021-06-21 · West Virginia University · Latanoprost ophthalmic solution“Funding unavailable”
- withdrawn · 2021-02-02 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · matched by the registry's drug synonymsNo reason given
- withdrawn · 2021-02-02 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · matched by the registry's drug synonymsNo reason given
- withdrawn · 2020-07-31 · Jonsson Comprehensive Cancer Center · bimatoprost ophthalmic solution“Study was never opened”
- terminated · 2019-05-29 · Alcon Research · Travoprost 0.004%/timolol 0.5% solution“Enrollment Challenges”
- terminated · 2019-05-02 · University College, London · matched by the registry's drug synonyms“Unable to maintain a functional laser in the environment”
- withdrawn · 2018-05-15 · Stanford University · matched by the registry's drug synonyms“Funding source unavailable”
- withdrawn · 2018-01-19 · Johns Hopkins University · matched by the registry's drug synonyms“Difficulty obtaining IDE by the FDA. Currently not worthwhile to pursue further.”
- terminated · 2017-07-25 · CHU de Quebec-Universite Laval · Generic latanoprost, Brand-name latanoprost“Problem with IP supply”
- terminated · 2017-03-17 · Allergan · BimatoprostNo reason given
- terminated · 2017-03-16 · Massachusetts Eye and Ear Infirmary · Travoprost, Latanoprost“Slow Enrollment”
- terminated · 2015-10-02 · Allergan · bimatoprost ophthalmic solution formulation A, bimatoprost vehicle“Study terminated due to corporate decision.”
Paediatric incentives and obligations for PTGFR's drugs
For dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, AL-12182: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PTGFR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001187-PIP01-11-M04 (tafluprost, Treatment of glaucoma): PM: decision on the application for modification of an agreed PIP, 17 Mar 2017; EMEA-001271-PIP01-12-M01 (travoprost, Treatment of glaucoma): PM: decision on the application for modification of an agreed PIP, 29 Nov 2013; compliance positive 23 May 2014; EMEA-002175-PIP01-17 (netarsudil;Latanoprost, Treatment of glaucoma): W: decision granting a waiver in all age groups for all conditions or indications, 4 Oct 2017; EMEA-000917-PIP01-10-M04 (bimatoprost, Treatment of glaucoma;Treatment of non-scarring hair loss): PM: decision on the application for modification of an agreed PIP, 30 Oct 2014; +4 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, al-12182Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Roclanda: authorised since 7 Jan 2021; DuoTrav: authorised since 23 Apr 2006; Travatan: authorised since 27 Nov 2001; Izba: authorised since 20 Feb 2014; +4 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, al-12182Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 29 interventional studies of dinoprost tromethamine, carboprost tromethamine, travoprost, bimatoprost, latanoprostene bunod, latanoprost, tafluprost, dinoprost, sepetaprost, al-12182 include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 11 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.